JP2019531357A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531357A5 JP2019531357A5 JP2019542356A JP2019542356A JP2019531357A5 JP 2019531357 A5 JP2019531357 A5 JP 2019531357A5 JP 2019542356 A JP2019542356 A JP 2019542356A JP 2019542356 A JP2019542356 A JP 2019542356A JP 2019531357 A5 JP2019531357 A5 JP 2019531357A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- rnai agent
- subject
- doses
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022068684A JP7566815B2 (ja) | 2016-10-18 | 2022-04-19 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2024173304A JP7850215B2 (ja) | 2016-10-18 | 2024-10-02 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2025258789A JP2026062719A (ja) | 2016-10-18 | 2025-12-17 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409816P | 2016-10-18 | 2016-10-18 | |
| US62/409,816 | 2016-10-18 | ||
| US201662422028P | 2016-11-14 | 2016-11-14 | |
| US62/422,028 | 2016-11-14 | ||
| US201762472525P | 2017-03-16 | 2017-03-16 | |
| US62/472,525 | 2017-03-16 | ||
| US201762550426P | 2017-08-25 | 2017-08-25 | |
| US62/550,426 | 2017-08-25 | ||
| PCT/US2017/057218 WO2018075658A1 (en) | 2016-10-18 | 2017-10-18 | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022068684A Division JP7566815B2 (ja) | 2016-10-18 | 2022-04-19 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531357A JP2019531357A (ja) | 2019-10-31 |
| JP2019531357A5 true JP2019531357A5 (https=) | 2021-10-21 |
| JP7181881B2 JP7181881B2 (ja) | 2022-12-01 |
Family
ID=60388127
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542356A Active JP7181881B2 (ja) | 2016-10-18 | 2017-10-18 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2022068684A Active JP7566815B2 (ja) | 2016-10-18 | 2022-04-19 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2024173304A Active JP7850215B2 (ja) | 2016-10-18 | 2024-10-02 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2025258789A Pending JP2026062719A (ja) | 2016-10-18 | 2025-12-17 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022068684A Active JP7566815B2 (ja) | 2016-10-18 | 2022-04-19 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2024173304A Active JP7850215B2 (ja) | 2016-10-18 | 2024-10-02 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2025258789A Pending JP2026062719A (ja) | 2016-10-18 | 2025-12-17 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20180104360A1 (https=) |
| EP (2) | EP4397311A3 (https=) |
| JP (4) | JP7181881B2 (https=) |
| KR (3) | KR20250171391A (https=) |
| CN (4) | CN110088283A (https=) |
| AU (2) | AU2017346879B2 (https=) |
| CA (1) | CA3042423A1 (https=) |
| CL (1) | CL2019001047A1 (https=) |
| DK (1) | DK3529360T3 (https=) |
| ES (1) | ES2982911T3 (https=) |
| FI (1) | FI3529360T3 (https=) |
| HR (1) | HRP20240930T1 (https=) |
| HU (1) | HUE067712T2 (https=) |
| IL (1) | IL266066A (https=) |
| LT (1) | LT3529360T (https=) |
| MX (2) | MX2019004573A (https=) |
| PL (1) | PL3529360T3 (https=) |
| PT (1) | PT3529360T (https=) |
| RS (1) | RS65725B1 (https=) |
| SI (1) | SI3529360T1 (https=) |
| WO (1) | WO2018075658A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL292159B1 (en) | 2012-12-05 | 2026-04-01 | Alnylam Pharmaceuticals Inc | PCSK9 iRNA compositions and methods of using them |
| CN108348541A (zh) | 2015-08-25 | 2018-07-31 | 阿尔尼拉姆医药品有限公司 | 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
| EP4397311A3 (en) | 2016-10-18 | 2024-10-16 | Novartis AG | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction |
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| EP3719126B1 (en) | 2017-12-01 | 2025-01-01 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| CA3083970A1 (en) | 2017-12-01 | 2019-06-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| DK3719128T3 (da) | 2017-12-01 | 2025-03-03 | Suzhou Ribo Life Science Co Ltd | Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf |
| EP3719127A4 (en) | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| AU2018394875B2 (en) | 2017-12-29 | 2023-08-03 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
| WO2020135673A1 (zh) | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| MX2021008661A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| BR112021013807A2 (pt) | 2019-01-18 | 2021-11-30 | Astrazeneca Ab | Inibidores de pcsk9 e seus métodos de uso |
| KR20220011689A (ko) | 2019-05-22 | 2022-01-28 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도 |
| US12590304B2 (en) | 2019-05-22 | 2026-03-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| AU2020280439B2 (en) | 2019-05-22 | 2025-08-14 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN115066498A (zh) | 2020-03-16 | 2022-09-16 | 阿尔戈诺特Rna有限公司 | Pcsk9的拮抗剂 |
| JP2025531341A (ja) * | 2022-09-19 | 2025-09-19 | カイロンノヴァ （シャーメン） バイオファーマ カンパニー，リミテッド | 炭水化物－オリゴヌクレオチド複合体、薬物組成物および治療への応用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101484588B (zh) * | 2006-05-11 | 2013-11-06 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
| IL292159B1 (en) | 2012-12-05 | 2026-04-01 | Alnylam Pharmaceuticals Inc | PCSK9 iRNA compositions and methods of using them |
| CN108348541A (zh) * | 2015-08-25 | 2018-07-31 | 阿尔尼拉姆医药品有限公司 | 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
| EP4397311A3 (en) | 2016-10-18 | 2024-10-16 | Novartis AG | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction |
-
2017
- 2017-10-18 EP EP24170268.7A patent/EP4397311A3/en active Pending
- 2017-10-18 CA CA3042423A patent/CA3042423A1/en active Pending
- 2017-10-18 HU HUE17800976A patent/HUE067712T2/hu unknown
- 2017-10-18 MX MX2019004573A patent/MX2019004573A/es unknown
- 2017-10-18 CN CN201780077941.7A patent/CN110088283A/zh not_active Withdrawn
- 2017-10-18 PL PL17800976.7T patent/PL3529360T3/pl unknown
- 2017-10-18 RS RS20240774A patent/RS65725B1/sr unknown
- 2017-10-18 WO PCT/US2017/057218 patent/WO2018075658A1/en not_active Ceased
- 2017-10-18 CN CN202411482008.6A patent/CN119700800A/zh active Pending
- 2017-10-18 SI SI201731532T patent/SI3529360T1/sl unknown
- 2017-10-18 ES ES17800976T patent/ES2982911T3/es active Active
- 2017-10-18 US US15/787,405 patent/US20180104360A1/en not_active Abandoned
- 2017-10-18 KR KR1020257038513A patent/KR20250171391A/ko active Pending
- 2017-10-18 DK DK17800976.7T patent/DK3529360T3/da active
- 2017-10-18 KR KR1020247014347A patent/KR20240067272A/ko not_active Ceased
- 2017-10-18 PT PT178009767T patent/PT3529360T/pt unknown
- 2017-10-18 JP JP2019542356A patent/JP7181881B2/ja active Active
- 2017-10-18 CN CN202411481996.2A patent/CN119345221A/zh active Pending
- 2017-10-18 HR HRP20240930TT patent/HRP20240930T1/hr unknown
- 2017-10-18 KR KR1020197014059A patent/KR20190077411A/ko not_active Ceased
- 2017-10-18 FI FIEP17800976.7T patent/FI3529360T3/fi active
- 2017-10-18 AU AU2017346879A patent/AU2017346879B2/en active Active
- 2017-10-18 LT LTEPPCT/US2017/057218T patent/LT3529360T/lt unknown
- 2017-10-18 CN CN202411479127.6A patent/CN119318663A/zh active Pending
- 2017-10-18 EP EP17800976.7A patent/EP3529360B1/en active Active
-
2019
- 2019-04-16 IL IL266066A patent/IL266066A/en unknown
- 2019-04-17 CL CL2019001047A patent/CL2019001047A1/es unknown
- 2019-04-17 MX MX2024004495A patent/MX2024004495A/es unknown
-
2020
- 2020-06-22 US US16/908,517 patent/US20210093736A1/en active Pending
-
2022
- 2022-04-19 JP JP2022068684A patent/JP7566815B2/ja active Active
-
2023
- 2023-11-09 AU AU2023263519A patent/AU2023263519B2/en active Active
-
2024
- 2024-10-02 JP JP2024173304A patent/JP7850215B2/ja active Active
-
2025
- 2025-12-17 JP JP2025258789A patent/JP2026062719A/ja active Pending
- 2025-12-22 US US19/429,048 patent/US20260108631A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531357A5 (https=) | ||
| FI3529360T3 (fi) | Menetelmiä sydän- ja verisuonitapahtumien ennaltaehkäisemiseksi proproteiini-konvertaasi-subtilisiini-keksiini tyyppi 9 (pcsk9) -proteiinia vähentämällä | |
| Pistolesi et al. | A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy | |
| Hörl | Iron therapy for renal anemia: how much needed, how much harmful? | |
| Smith et al. | Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime | |
| JP2023549115A5 (https=) | ||
| JP2011511004A5 (https=) | ||
| EP2601949A2 (en) | Pharmaceutical compositions | |
| JP2018087228A (ja) | がんのためのグルフォスファミド組み合わせ療法 | |
| JP2019206562A5 (https=) | ||
| JP2019518028A5 (https=) | ||
| JP7829478B2 (ja) | Ａｐｏｃ３関連疾患および障害の処置のための方法 | |
| KR20190075968A (ko) | 심혈관-관련 질환의 치료를 위한 아펠린의 신규 peg화 리포솜 제제 | |
| Perkins et al. | No need to sugarcoat the message: is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis? | |
| Leitch et al. | Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy | |
| Goldenberg et al. | Managing the course of kidney disease in adults with type 2 diabetes: from the old to the new | |
| JP7221956B2 (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| Goldberg | Novel therapies and new targets of treatment for familial hypercholesterolemia | |
| KR20250054795A (ko) | Angptl3-관련 질환 및 장애의 치료 방법 | |
| CN115120724A (zh) | 治疗再生障碍性贫血的方法和药物组合物 | |
| Sanchez et al. | Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease | |
| Zhang et al. | The use of nicardipine for electroconvulsive therapy: a dose-ranging study | |
| Littlewood et al. | The use of intravenous iron in patients with cancer‐related anaemia | |
| Qunibi | Is it too much of a good thing? A new era in phosphate binder therapy in ESRD | |
| Masood et al. | Pharmacological Adjuvants to Limit Erythropoietin Stimulating Agents Exposure |